[Form 3] Can-Fite BioPharma Ltd. Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. director Yoseph Bornstein filed an initial Form 3 reporting his holdings of stock options to purchase the company’s ordinary shares. The filing lists four option grants with different exercise prices, vesting schedules, and expiration dates.
One grant covers 200 underlying shares at an exercise price of $241.47, fully vested and expiring on June 22, 2031. Two additional grants each relate to 2,166 underlying shares, with exercise prices of $25.21 and $26.56 and expirations on April 30, 2033 and May 7, 2034, respectively; portions of these are already vested and the rest vest in specified quarterly installments. A larger grant covers 16,000 underlying shares at an exercise price of $2.18, expiring on January 25, 2030, with all of these options vesting in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030.
The footnotes explain that, to qualify for certain Israeli tax benefits under Section 102, plan securities are held in the name of a trustee, and that the exercise prices were originally denominated in New Israeli Shekels and converted to U.S. dollars using a Bank of Israel exchange rate of 3.106 NIS per USD reported on March 11, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
Footnotes (1)
- To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. These options are fully vested and exercisable as of the date hereof. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 750, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 05/01/2026 and ending 05/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date. The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
